20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....
12:31 , Jun 13, 2019 |  BioCentury  |  Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners,...
22:48 , Jun 10, 2019 |  BC Extra  |  Politics & Policy

MPs, health secretary more open to compulsory licensing of CF drugs

The formation of a buyer's club in the U.K. may have pushed more MPs to support compulsory licensing of Vertex's cystic fibrosis drugs. At a Parliamentary debate Monday -- the fifth such debate over access...
22:49 , Jun 7, 2019 |  BC Extra  |  Financial News

Chipscreen set to test Shanghai’s new innovation board

Chipscreen could soon become the first biotech to list on the Shanghai Stock Exchange’s new science and technology innovation board after its application was approved this week. The application from Shenzhen Chipscreen Biosciences Ltd. (Shenzhen,...
03:11 , Jun 7, 2019 |  BC Extra  |  Company News

Exonics takeout, expanded CRISPR deal vault Vertex into neuromuscular diseases

Via a pair of deals totaling $420 million in upfront payments late Thursday, Vertex expanded into neuromuscular diseases and bolstered its gene editing capabilities by acquiring Exonics, broadening its partnership with CRISPR Therapeutics and hiring...
00:28 , Jun 7, 2019 |  BioCentury  |  Product Development

How early biomarkers and constant iteration fuel Vertex's R&D efficiency

As Vertex prepares its fourth NDA for a cystic fibrosis drug in six years, EVP of Global Research and CSO David Altshuler credits the biotech’s R&D efficiency to a focus on agents that show more...
00:12 , Jun 7, 2019 |  BC Extra  |  Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

Celgene resubmits NDA for ozanimod   FDA and EMA accepted submissions from Celgene Corp. (NASDAQ:CELG) for ozanimod to treat multiple sclerosis. The PDUFA date for the selective S1PR1 and S1PR5 modulator is March 25, 2020,...
00:24 , Jun 5, 2019 |  BC Extra  |  Company News

U.K. parents form group to buy generic versions of Vertex CF drugs

A group of parents who have children with cystic fibrosis have launched a buyer's club to purchase generic versions of drugs manufactured by Vertex from an undisclosed manufacturer, with the goal of convincing the U.K....
23:09 , Jun 4, 2019 |  BC Extra  |  Company News

Arvinas adds to momentum with Bayer deal for protein degraders

Arvinas is building on its recent momentum by signing Bayer as its fourth pharma partner in a deal announced Tuesday that aims to broaden its pipeline of protein degraders into new indications. The partnership comes...
21:36 , Jun 3, 2019 |  BC Extra  |  Company News

Management tracks: Zai, Jazz, PTC, BIO and more

Cancer company Zai Lab Ltd. (NASDAQ:ZLAB) hired Valeria Fantin as its first CSO. She was CSO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Cancer and neurology company Jazz Pharmaceuticals plc (NASDAQ:JAZZ) hired Robert Iannone...